Keynote Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Keynote Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$550K	Buy	1,231 +65	+6%	+$30.3K	0.29%	94
2025 Q4	$529K	Buy	1,166 +12	+1%	+$5.17K	0.3%	89
2025 Q3	$452K	Buy	1,154 +9	+0.8%	+$3.76K	0.27%	103
2025 Q2	$510K	Buy	1,145 +40	+4%	+$18.4K	0.34%	80
2025 Q1	$536K	Buy	1,105 +20	+2%	+$9.32K	0.38%	70
2024 Q4	$437K	Buy	1,085 +15	+1%	+$6.95K	0.34%	81
2024 Q3	$498K	Buy	+1,070	New	+$514K	0.38%	76

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Keynote Financial Services's VRTX Position: Q1 2026 in Review

Keynote Financial Services increased its Vertex Pharmaceuticals (VRTX) stake by 5.6% in Q1 2026, buying an estimated $30.3K and bringing the position to 1,231 shares worth $550K. The position accounts for 0.29% of the portfolio, ranked #94.

Keynote Financial Services first reported a position in VRTX in Q3 2024 and has held it in 7 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Keynote Financial Services held 1,231 shares of Vertex Pharmaceuticals worth $550K as of Q1 2026.
Keynote Financial Services bought 65 Vertex Pharmaceuticals shares in Q1 2026, an estimated $30.3K.
Vertex Pharmaceuticals made up 0.29% of Keynote Financial Services's portfolio in Q1 2026, its #94 holding.
Keynote Financial Services first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Keynote Financial Services's 13F filing for Q1 2026, filed 13 May 2026.